Advertisement

Thyrotropin releasing hormone (TRH): Restoration of oxotremorine tremor in mice

Comparison with quipazine, a serotoninergic and dopaminergic stimulant
  • Hansjörg Kruse
Article

Summary

Both TRH and quipazine (2.5–25 mg/kg) were found to restore and to intensify the oxotremorine-induced tremor in mice when injected i.p. 60 min after oxotremorine 0.5 mg/kg s.c. This phenomenon does not seem to be due to an increase in body temperature or muscle tone. Also other dopaminergic drugs, e.g. amphetamine, methylphenidate, nomifensine and apomorphine had a significant but lesser effect than TRH or quipazine. Haloperidol and methysergide both antagonized the effect of quipazine but not that of TRH. Neither propranolol, phenoxybenzamine, alpha-methyl-p-tyrosine, nor p-chlorophenylalanine inhibited the activity of TRH or quipazine. The restoration of oxotremorine-induced tremor could be prevented by atropine but not by methylatropine.

It is concluded that quipazine exerts its effect by direct stimulation of serotoninergic and dopaminergic receptors, whereas TRH receptors may represent separate entities and TRH may function as a neurotransmitter or neuromodulator.

Key words

Thyrotropin releasing hormone Quipazine Oxotremorine Tremor restoration Dopaminergic and serotoninergic receptor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fisher, R. A.: Statistical methods for research workers, pp. 96–97. London: Oliver and Boyd 1948Google Scholar
  2. Grabowska, M., Antkiewicz, L., Michaluk, J.: A possible interaction of quipazine with central dopamine structures. J. Pharm. Pharmacol.26, 74–76 (1974)Google Scholar
  3. Green, A. R., Grahame-Smith, D. G.: TRH potentiates behavioural changes following increased brain 5-hydroxytryptamine accumulation in rats. Nature (Lond.)252, 524–526 (1974)Google Scholar
  4. Grimm-Jørgensen, Y., McKelvy, J. F.: Immunoreactive thyrotropin releasing factor in gastropod circumoesophageal ganglia. Nature (Lond.)254, 620 (1975)Google Scholar
  5. Hong, E., Sancilio, L. F., Vargas, R., Pardo, E. G.: Similarities between the pharmacological actions of quipazine and serotonin. Europ. J. Pharmacol.6, 274–280 (1969)Google Scholar
  6. Kruse, H.: Neurotropic effects of thyrotropin releasing hormone (TRH). Naunyn-Schmiedeberg's Arch. Pharmacol.282, R 51 (1974)Google Scholar
  7. Kruse, H.: Thyrotropin releasing hormone: Interaction with chlorpromazine in mice, rats and rabbits. J. Pharmacol. (Paris)6, 249–268 (1975a)Google Scholar
  8. Kruse, H.: Thyrotropin releasing hormone (TRH): Comparison with a serotoninergic stimulant in oxotremorine and chlorpromazine treated mice. Sixth International Congress of Pharmacology, Helsinki, July 1975. Abstracts204, p. 94 (1975b)Google Scholar
  9. Longo, V. G., Huidobro-Toro, J. P., Scotti de Carolis, A.: Intensification of central catecholaminergic and serotoninergic processes by the hypothalamic factors MIF and RF. J. Pharmacol. (Paris),5, Suppl. 1, 87–88 (1974)Google Scholar
  10. Medon, P. J., Leeling, J. L., Phillips, B. M.: Influence of quipazine, a potential antiparkinsonian agent on the uptake of3H-dopamine and3H-serotonin into rat striatal tissue in vitro. Life Sci.13, 685–691 (1973)Google Scholar
  11. Oliver, C., Taurog, A., Porter, J. C.: Physiologie de la secretion de la T.R.H. Nouv. Presse Med.3, 1941–1944 (1974)Google Scholar
  12. Rodriguez, R.: Antagonism of tremorine-induced tremor by serotoninergic agents in mice. Interactions with levodopa. Life Sci.11, 535–544 (1972)Google Scholar
  13. Rodriguez, R., Rojas-Ramirez, J. A., Drucker-Colin, R. R.: Serotonin-like actions of quipazine on the central nervous system. Europ. J. Pharmacol.24, 164–171 (1973)Google Scholar

Copyright information

© Springer-Verlag 1976

Authors and Affiliations

  • Hansjörg Kruse
    • 1
  1. 1.Hoechst AktiengesellschaftFrankfurt a. M.Germany

Personalised recommendations